Avneet Sodhi-Gaur, MD
Ophthalmology · Lancaster, CANPI 1982929105
Payments from drug & device makers
Across 282 payments — averaging $128.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$16K
- Glaukos Corporation$10K
- AbbVie$2K
- Lumenis BE Inc$2K
- Nova Eye, Inc.$1K
- Bausch & Lomb Americas Inc.$1K
- plus $4K from 20 others
Across 1 payment — averaging $2080.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$2K
What the payments were for
- Speaking & faculty fees$15,48855%
- Travel & lodging$1,2524%
- Food & beverage$11,16040%
- Education$80%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 38 | $16,497 |
| Glaukos Corporation | 16 | $10,055 |
| AbbVie(2 entities) | 85 | $1,914 |
| Lumenis BE Inc | 1 | $1,571 |
| Nova Eye, Inc. | 3 | $1,356 |
| Bausch & Lomb Americas Inc. | 32 | $1,078 |
| Sun Pharmaceutical Industries Inc. | 17 | $615 |
| Alcon | 10 | $474 |
| Thea Pharma Inc. | 17 | $364 |
| Revance Therapeutics, Inc. | 7 | $344 |
| Amgen | 6 | $264 |
| NEW World Medical,inc. | 3 | $249 |
| Tarsus Pharmaceuticals, Inc. | 9 | $208 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $203 |
| Dompe US, Inc. | 5 | $168 |
| Mallinckrodt Hospital Products Inc. | 5 | $144 |
| Ivantis, Inc | 1 | $124 |
| Biotissue Holdings Inc. | 1 | $121 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $110 |
| Ocular Therapeutix, Inc. | 4 | $84 |
| Oyster Point Pharma, Inc. | 3 | $68 |
| Akorn Operating Company LLC | 3 | $57 |
| Astellas Pharma US Inc | 1 | $28 |
| Aerie Pharmaceuticals, Inc. | 1 | $24 |
| Akorn, Inc. | 1 | $17 |
| Rxsight Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$13,301
- OMNI$2,125
- optilight$1,571
- SION SURGICAL INSTRUMENT$500
- MIEBO$293
- XIIDRA$293
- Kahook Dual Blade$157
- Streamline Surgical System$157
- Ahmed Glaucoma Valve$157
- Hydrus$124
- KXL System$123
- Photrexa$123
- Prokera$121
- CEQUA$121
- TEPEZZA$121
- LOTEMAX SM$109
How this compares
$36,152 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 185 | $78,834 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 127 | $28,191 |
| Alphagan PBrimonidine Tartrate | 83 | $26,500 |
| CombiganBrimonidine Tartrate/Timolol | 76 | $25,751 |
| RestasisCyclosporine | 30 | $22,467 |
| RocklatanNetarsudil Mesylat/Latanoprost | 39 | $21,212 |
| RhopressaNetarsudil Mesylate | 49 | $16,961 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 103 | $16,684 |
| Cyclosporine | 59 | $16,332 |
| Brimonidine Tartrate | 173 | $15,703 |
| ProlensaBromfenac Sodium | 34 | $11,393 |
| TafluprostTafluprost/Pf | 66 | $11,256 |
| MieboPerfluorohexyloctane/Pf | 15 | $11,190 |
| VyzultaLatanoprostene Bunod | 21 | $9,241 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 73 | $8,877 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $1,914 | $153,552374 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $24 | $38,17388 claims |
| AlconSimbrinza | $474 | $28,191127 claims |
| Bausch & Lomb Americas Inc.Miebo, Vyzulta | $1,078 | $20,43136 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $110 | $11,39334 claims |
| Akorn, Inc.Betimol | $17 | $2,43012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Lancaster
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.